Current Report Filing (8-k)
July 26 2021 - 7:41AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report: July 26, 2021
InspireMD,
Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
001-35731
|
|
26-2123838
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
4
Menorat Hamaor St.
Tel
Aviv, Israel
|
|
6744832
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(888)
776-6804
(Registrant’s
Telephone Number, Including Area Code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Common
Stock, par value $0.0001 per share
|
|
NSPR
|
|
The
Nasdaq Capital Market
LLC
|
|
Series
B Warrants, exercisable for one share of Common Stock
|
|
NSPRZ
|
|
The
Nasdaq Capital Market
LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01 Other Events.
On
July 23, 2021, InspireMD, Inc. (the “Company”) issued a press release announcing the initial enrollment and completion of
the first cases of the Company’s C-Guardian trial of its CGuard™ Embolic Prevention Stent System.
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
INSPIREMD,
INC.
|
|
|
|
|
Date:
July 26, 2021
|
By:
|
/s/
Craig Shore
|
|
|
Name:
|
Craig
Shore
|
|
|
Title:
|
Chief
Financial Officer
|
InspireMD (NASDAQ:NSPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
InspireMD (NASDAQ:NSPR)
Historical Stock Chart
From Apr 2023 to Apr 2024
